Recurrent Pulmonary Embolism Associated with a New Mutation Site of SLC44A2: A Case Report

References (1)

1. Leong IUS, Stuckey A, Lai D, Skinner JR, Love DR. Assessment of the predictive accuracy of five in silico prediction tools, alone or in combination, and two metaservers to classify long QT syn- drome gene mutations. BMC Med Genet. 2015;16(1):34. [CrossRef] 2. Zhang F, Gui Y, Lu Y, et al. Novel SERPINC1 missense mutation (Cys462Tyr) causes disruption of the 279Cys-462Cys disulfide bond and leads to type - hereditary antithrombin deficiency. Clin Biochem. 2020;85:38-42. [CrossRef] 3. Chen X, Li X, Xu X, et al. Ferroptosis and cardiovascular disease: role of free radical-induced lipid peroxidation. Free Radic Res. 2021;55(4):405-415. [CrossRef] 4. Khan F, Rahman A, Carrier M, et al. Long term risk of sympto- matic recurrent venous thromboembolism after discontinua- tion of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363. [CrossRef] 5. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. [CrossRef] 6. Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ. 2020;370: m2177. [CrossRef]